Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Generic name: florbetaben f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2025
Generic Entry Controlled by: Canada Patent 2,591,534
Patent Title: DERIVES DE STILBENE ET LEUR UTILISATION POUR LA LIAISON ET L'IMAGERIE DE PLAQUES AMYLOIDES (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)

NEURACEQ is a drug marketed by Life Molecular. There are two patents protecting this drug.

This drug has sixty-two patent family members in thirty-one countries. There has been litigation on patents covering NEURACEQ

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.

Generic name: lorcaserin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2025
Generic Entry Controlled by: Canada Patent 2,589,988
Patent Title: FORMES CRISTALLINES D'HYDROCHLORURE DE (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE (CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL- 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE HYDROCHLORIDE)

BELVIQ is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has sixty-two patent family members in thirty-one countries. There has been litigation on patents covering BELVIQ

See drug price trends for BELVIQ.

The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.

Generic name: selumetinib sulfate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2025
Generic Entry Controlled by: Canada Patent 2,634,149
Patent Title: NOUVEAU SEL HYDROGENOSULFATE (NOVEL HYDROGEN SULFATE SALT)

KOSELUGO is a drug marketed by Astrazeneca. There are eight patents protecting this drug.

This drug has two hundred and one patent family members in forty-five countries. There has been litigation on patents covering KOSELUGO

See drug price trends for KOSELUGO.

The generic ingredient in KOSELUGO is selumetinib sulfate. One supplier is listed for this generic product. Additional details are available on the selumetinib sulfate profile page.

Generic name: diazoxide choline
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2026
Generic Entry Controlled by: Canada Patent 2,636,274
Patent Title: SELS D'OUVREURS DES CANAUX POTASSIQUES ATP-DEPENDANTS ET LEURS UTILISATIONS (SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF)

VYKAT XR is a drug marketed by Soleno Therap. There are six patents protecting this drug.

This drug has seventy-eight patent family members in twenty-two countries.

The generic ingredient in VYKAT XR is diazoxide choline. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the diazoxide choline profile page.

Generic name: levoketoconazole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2026
Generic Entry Controlled by: Canada Patent 2,594,433
Patent Title: PROCEDES ET COMPOSITIONS POUR LE TRAITEMENT DU DIABETE, DU SYNDROME METABOLIQUE ET D'AUTRES CONDITIONS (METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS)

RECORLEV is a drug marketed by Strongbridge. There are nine patents protecting this drug.

This drug has thirty-six patent family members in twenty-one countries.

See drug price trends for RECORLEV.

The generic ingredient in RECORLEV is levoketoconazole. One supplier is listed for this generic product. Additional details are available on the levoketoconazole profile page.

Generic name: bendamustine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 13, 2026
Generic Entry Controlled by: Canada Patent 2,593,582
Patent Title: COMPOSITIONS PHARMACEUTIQUES DE BENDAMUSTINE (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)

BELRAPZO is a drug marketed by Eagle Pharms. There are eleven patents protecting this drug. Six tentatively approved generics are ready to enter the market.

This drug has sixty-five patent family members in thirty countries. There has been litigation on patents covering BELRAPZO

See drug price trends for BELRAPZO.

The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

Generic name: bendamustine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 13, 2026
Generic Entry Controlled by: Canada Patent 2,593,582
Patent Title: COMPOSITIONS PHARMACEUTIQUES DE BENDAMUSTINE (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)

BENDEKA is a drug marketed by Eagle Pharms. There are twenty patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty-five patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA

See drug price trends for BENDEKA.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

Generic name: leuprolide mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 18, 2026
Generic Entry Controlled by: Canada Patent 2,637,569
Patent Title: COMPOSITIONS PHARMACEUTIQUES A STABILITE AMELIOREE (PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY)

CAMCEVI KIT is a drug marketed by Accord. There are five patents protecting this drug.

This drug has thirty-nine patent family members in nineteen countries.

The generic ingredient in CAMCEVI KIT is leuprolide mesylate. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the leuprolide mesylate profile page.

Generic name: lubiprostone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2026
Generic Entry Controlled by: Canada Patent 2,637,274
Patent Title: FORMULATION DE CAPSULE GELATINEUSE MOLLE (SOFT-GELATIN CAPSULE FORMULATION)

AMITIZA is a drug marketed by Sucampo Pharma Llc. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in nineteen countries. There has been litigation on patents covering AMITIZA

See drug price trends for AMITIZA.

The generic ingredient in AMITIZA is lubiprostone. There are ten drug master file entries for this API. Twenty suppliers are listed for this generic product. Additional details are available on the lubiprostone profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2026
Generic Entry Controlled by: Canada Patent 2,602,042
Patent Title: TROUSSE ET COMPOSITION D'IMIDAZOLE PRESENTANT UNE BIODISPONIBILITE ACCRUE (KIT AND COMPOSITION OF IMIDAZOLE WITH ENHANCED BIOAVAILABILITY)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: methotrexate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2026
Generic Entry Controlled by: Canada Patent 2,595,730
Patent Title: INJECTEUR A SERINGUE PREREMPLIE ASSISTE D'UNE AIGUILLE (PREFILLED NEEDLE ASSISTED JET INJECTOR)

OTREXUP is a drug marketed by Assertio Speclty. There are fifteen patents protecting this drug.

This drug has thirty-nine patent family members in fourteen countries. There has been litigation on patents covering OTREXUP

See drug price trends for OTREXUP.

The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

Generic name: regadenoson
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 03, 2026
Generic Entry Controlled by: Canada Patent 2,640,089
Patent Title: PROCEDE DE PREPARATION D'UN AGONISTE DE RECEPTEUR A2A-ADENOSINE ET SES POLYMORPHES (PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS)

LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in eighteen countries. There has been litigation on patents covering LEXISCAN

See drug price trends for LEXISCAN.

The generic ingredient in LEXISCAN is regadenoson. There are nine drug master file entries for this API. Eighteen suppliers are listed for this generic product. Additional details are available on the regadenoson profile page.

Generic name: pitolisant hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 06, 2026
Generic Entry Controlled by: Canada Patent 2,597,016
Patent Title: SEL DE MONOHYDROCHLORURE DE 1-[3-[3-(4-CHLOROPHENYL)PROPOXY]PROPYL]-PIPERIDINE (MONOHYDROCHLORIDE SALT OF 1- [3- [3- (4-CHLOROPHENYL) PROPOXY] PROPYL] -PIPERIDINE)

WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.

This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX

See drug price trends for WAKIX.

The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.

Generic name: peramivir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2026
Generic Entry Controlled by: Canada Patent 2,642,260
Patent Title: TRAITEMENTS ANTIVIRAUX INTRAVEINEUX (INTRAVENOUS ANTIVIRAL TREATMENTS)

RAPIVAB is a drug marketed by Biocryst. There are two patents protecting this drug.

This drug has forty-three patent family members in fourteen countries.

See drug price trends for RAPIVAB.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.

Generic name: peramivir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2026
Generic Entry Controlled by: Canada Patent 2,649,090
Patent Title: TRAITEMENTS ANTIVIRAUX INTRAMUSCULAIRES (INTRAMUSCULAR ANTIVIRAL TREATMENTS)

RAPIVAB is a drug marketed by Biocryst. There are two patents protecting this drug.

This drug has forty-three patent family members in fourteen countries.

See drug price trends for RAPIVAB.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.

Generic name: avacincaptad pegol sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2026
Generic Entry Controlled by: Canada Patent 2,597,889
Patent Title: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)

IZERVAY is a drug marketed by Astellas. There are nine patents protecting this drug.

This drug has one hundred and five patent family members in twenty-nine countries.

See drug price trends for IZERVAY.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.

Generic name: avacincaptad pegol sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2026
Generic Entry Controlled by: Canada Patent 2,897,900
Patent Title: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)

IZERVAY is a drug marketed by Astellas. There are nine patents protecting this drug.

This drug has one hundred and five patent family members in twenty-nine countries.

See drug price trends for IZERVAY.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.

Generic name: avacincaptad pegol sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2026
Generic Entry Controlled by: Canada Patent 2,992,874
Patent Title: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)

IZERVAY is a drug marketed by Astellas. There are nine patents protecting this drug.

This drug has one hundred and five patent family members in twenty-nine countries.

See drug price trends for IZERVAY.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.

Generic name: avacincaptad pegol sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2026
Generic Entry Controlled by: Canada Patent 3,124,030
Patent Title: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)

IZERVAY is a drug marketed by Astellas. There are nine patents protecting this drug.

This drug has one hundred and five patent family members in twenty-nine countries.

See drug price trends for IZERVAY.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2026
Generic Entry Controlled by: Canada Patent 2,597,982
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2026
Generic Entry Controlled by: Canada Patent 2,597,982
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)

KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: sorafenib tosylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 22, 2026
Generic Entry Controlled by: Canada Patent 2,601,955
Patent Title: COMPOSITION PHARMACEUTIQUE COMPRENANT UNE DIPHENYLUREE SUBSTITUEE PAR UN OMEGA-CARBOXYARYLE POUR LE TRAITEMENT DU CANCER (PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA- CARBOXYARYL SUBSTITUTED DIPHENYL UREA FOR THE TREATMENT OF CANCER)

NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR

See drug price trends for NEXAVAR.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.

Generic name: hyaluronidase recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2026
Generic Entry Controlled by: Canada Patent 2,598,823
Patent Title: GLYCOSAMINOGLYCANASES SOLUBLES ET PROCEDES DE PREPARATION ETD'UTILISATION DE GLYCOSAMINOGLYCANASES SOLUBLES (SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES)

HYLENEX RECOMBINANT is a drug marketed by

This drug has eighty-nine patent family members in thirty-nine countries.

The generic ingredient in HYLENEX RECOMBINANT is hyaluronidase recombinant human. There are six drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the hyaluronidase recombinant human profile page.

Generic name: ivabradine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 24, 2026
Generic Entry Controlled by: Canada Patent 2,537,400
Patent Title: FORME CRISTALLINE Y DU CHLORHYDRATE DE L'IVABRADINE, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT (Y CRYSTALLINE FORM OF IVABRADINE CHLORHYDRATE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOUNDS CONTAINING IT)

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

Generic name: ivabradine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 24, 2026
Generic Entry Controlled by: Canada Patent 2,537,414
Patent Title: FORME CRISTALLINE B DU CHLORHYDRATE DE L'IVABRADINE, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT (B CRYSTALLINE FORM OF IVABRADINE CHLORHYDRATE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOUNDS CONTAINING IT)

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

Generic name: rifaximin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 27, 2026
Generic Entry Controlled by: Canada Patent 2,594,789
Patent Title: NOUVELLES FORMES POLYMORPHES DE RIFAXIMINE, LEURS PROCEDES DE PREPARATION ET LEUR UTILISATION EN MEDECINE (NEW POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL)

XIFAXAN is a drug marketed by Salix Pharms. There are twenty-two patents protecting this drug and two Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering XIFAXAN

See drug price trends for XIFAXAN.

The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.

Generic name: metformin hydrochloride; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 13, 2026
Generic Entry Controlled by: Canada Patent 2,601,501
Patent Title: NOUVELLE FORMULATION PHARMACEUTIQUE CONTENANT UN BIGUANIDE ET UN DERIVE DE THIAZOLIDINEDIONE (NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE)

ACTOPLUS MET XR is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-two patent family members in twenty-five countries. There has been litigation on patents covering ACTOPLUS MET XR

See drug price trends for ACTOPLUS MET XR.

The generic ingredient in ACTOPLUS MET XR is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.

Generic name: mechlorethamine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2026
Generic Entry Controlled by: Canada Patent 2,600,468
Patent Title: COMPOSITIONS STABILISEES D'AGENTS D'ALKYLATION VOLATILS ET METHODES D'UTILISATION DE CES COMPOSITIONS (STABILIZED COMPOSITIONS OF VOLATILE ALKYLATING AGENTS AND METHODS OF USING THEREOF)

VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.

This drug has fifty patent family members in twenty countries.

See drug price trends for VALCHLOR.

The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.

Generic name: semaglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2026
Generic Entry Controlled by: Canada Patent 2,601,784
Patent Title: COMPOSES DE GLP-1 ACYLES (ACYLATED GLP-1 COMPOUNDS)

OZEMPIC is a drug marketed by Novo. There are nineteen patents protecting this drug.

This drug has two hundred and thirty-eight patent family members in thirty-three countries. There has been litigation on patents covering OZEMPIC

See drug price trends for OZEMPIC.

The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

Generic name: semaglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2026
Generic Entry Controlled by: Canada Patent 2,601,784
Patent Title: COMPOSES DE GLP-1 ACYLES (ACYLATED GLP-1 COMPOUNDS)

WEGOVY is a drug marketed by Novo. There are nine patents protecting this drug.

This drug has one hundred and eighty patent family members in thirty-three countries. There has been litigation on patents covering WEGOVY

See drug price trends for WEGOVY.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

Generic name: belumosudil mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 27, 2026
Generic Entry Controlled by: Canada Patent 2,602,254
Patent Title: COMPOSES PHARMACOCINETIQUEMENT AMELIORES (PHARMACOKINETICALLY IMPROVED COMPOUNDS)

REZUROCK is a drug marketed by Kadmon Pharms Llc. There are five patents protecting this drug.

This drug has fifty-seven patent family members in twenty-nine countries.

See drug price trends for REZUROCK.

The generic ingredient in REZUROCK is belumosudil mesylate. One supplier is listed for this generic product. Additional details are available on the belumosudil mesylate profile page.

Generic name: enzalutamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2026
Generic Entry Controlled by: Canada Patent 2,608,436
Patent Title: COMPOSES DIARYLHYDANTOINES (DIARYLHYDANTOIN COMPOUNDS)

XTANDI is a drug marketed by Astellas. There are five patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and ninety-one patent family members in thirty-five countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

Generic name: alcaftadine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 31, 2026
Generic Entry Controlled by: Canada Patent 2,648,115
Patent Title: TRAITEMENTS DE L'ALLERGIE OCULAIRE (OCULAR ALLERGY TREATMENTS)

LASTACAFT is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT

See drug price trends for LASTACAFT.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 06, 2026
Generic Entry Controlled by: Canada Patent 2,604,052
Patent Title: PROCEDES ET COMPOSITIONS POUR LE TRAITEMENT DES PATHOLOGIES ASSOCIEES AU SYSTEME NERVEUX CENTRAL (METHODS AND COMPOSITIONS FOR TREATMENT OF CNS DISORDERS)

NAMZARIC is a drug marketed by Abbvie. There are six patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: lisdexamfetamine dimesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 10, 2026
Generic Entry Controlled by: Canada Patent 2,603,873
Patent Title: PROMEDICAMENTS A BASE D'AMPHETAMINE RESISTANTS A LA CONSOMMATION ABUSIVE (ABUSE-RESISTANT AMPHETAMINE PRODRUGS)

VYVANSE is a drug marketed by Takeda Pharms Usa.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering VYVANSE

See drug price trends for VYVANSE.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Twenty suppliers are listed for this generic product. Additional details are available on the lisdexamfetamine dimesylate profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2026
Generic Entry Controlled by: Canada Patent 2,604,943
Patent Title: SYSTEMES D'APPORT DE SUBSTANCES PHARMACEUTIQUES DESTINES A DES MEDICAMENTS HYDROPHOBES ET COMPOSITIONS COMPRENANT CES DERNIERS (PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME)

JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 17, 2026
Generic Entry Controlled by: Canada Patent 2,605,299
Patent Title: REGIME CONTRACEPTIF DE DOSAGE D'ESTROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)

LO LOESTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has nine patent family members in seven countries. There has been litigation on patents covering LO LOESTRIN FE

See drug price trends for LO LOESTRIN FE.

The generic ingredient in LO LOESTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 17, 2026
Generic Entry Controlled by: Canada Patent 2,605,299
Patent Title: REGIME CONTRACEPTIF DE DOSAGE D'ESTROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)

LO MINASTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has nine patent family members in seven countries. There has been litigation on patents covering LO MINASTRIN FE

The generic ingredient in LO MINASTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 18, 2026
Generic Entry Controlled by: Canada Patent 2,606,933
Patent Title: TROUSSE DE STEROIDES, COMPOSITION MOUSSANTE ET UTILISATIONS (STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: lapatinib ditosylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 18, 2026
Generic Entry Controlled by: Canada Patent 2,606,207
Patent Title: PREPARATION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)

TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-six countries.

See drug price trends for TYKERB.

The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.

Generic name: eslicarbazepine acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2026
Generic Entry Controlled by: Canada Patent 2,616,984
Patent Title: REDUCTION CATALYTIQUE ASYMETRIQUE D'OXCARBAZEPINE (ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE)

APTIOM is a drug marketed by Sumitomo Pharma Am. There are eleven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering APTIOM

See drug price trends for APTIOM.

The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.

Generic name: cenobamate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2026
Generic Entry Controlled by: Canada Patent 2,606,258
Patent Title: COMPOSES AZOLE NEUROTHERAPEUTIQUES (NEUROTHERAPEUTIC AZOLE COMPOUNDS)

XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-six patent family members in twenty countries. There has been litigation on patents covering XCOPRI

See drug price trends for XCOPRI.

The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2026
Generic Entry Controlled by: Canada Patent 2,606,282
Patent Title: DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASEINHIBITORY ACTIVITY)

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-six patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: linagliptin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 04, 2026
Generic Entry Controlled by: Canada Patent 2,649,922

TRADJENTA is a drug marketed by Boehringer Ingelheim. There are eleven patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has four hundred and eighty-six patent family members in forty-five countries. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2026
Generic Entry Controlled by: Canada Patent 2,609,948
Patent Title: TROUSSE ET COMPOSITION VASOACTIVE ET LEURS UTILISATIONS (VASOACTIVE KIT AND COMPOSITION AND USES THEREOF)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 09, 2026
Generic Entry Controlled by: Canada Patent 2,609,953
Patent Title: COMPOSITIONS EXPANSIBLES SACCHARIDIQUES (SACCHARIDE FOAMABLE COMPOSITIONS)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 09, 2026
Generic Entry Controlled by: Canada Patent 2,610,662
Patent Title: EXCIPIENT EXPANSIBLE ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CELUI-CI (FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: belinostat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2026
Generic Entry Controlled by: Canada Patent 2,606,598
Patent Title: FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE HDAC (PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS)

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

Generic name: bosentan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 15, 2026
Generic Entry Controlled by: Canada Patent 2,607,098
Patent Title: COMPRIME DISPERSIBLE (DISPERSIBLE BOSERTAN TABLET)

TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER

See drug price trends for TRACLEER.

The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.

Generic name: lurasidone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2026
Generic Entry Controlled by: Canada Patent 2,606,510
Patent Title: COMPOSITION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)

LATUDA is a drug marketed by Sunovion Pharms Inc. There are seven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-eight patent family members in twenty-three countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Thirty suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

Generic name: boceprevir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2026
Generic Entry Controlled by: Canada Patent 2,611,155
Patent Title: FORMULATIONS PHARMACEUTIQUES ET METHODES DE TRAITEMENT UTILISANT CES FORMULATIONS (COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT)

VICTRELIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has twenty-seven patent family members in seventeen countries.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 05, 2026
Generic Entry Controlled by: Canada Patent 2,609,401
Patent Title: PREPARATIONS DE PEPTIDES AGONISTES DU RECEPTEUR DE L'ERYTHROPOIETINE ET UTILISATIONS (ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES)

OMONTYS is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 07, 2026
Generic Entry Controlled by: Canada Patent 2,611,577
Patent Title: KIT ET COMPOSITION ANTIBIOTIQUES ET LEURS UTILISATIONS (ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2026
Generic Entry Controlled by: Canada Patent 2,655,835

EMBEDA is a drug marketed by Alpharma Pharms. There are nine patents protecting this drug and four Paragraph IV challenges.

This drug has seventy-four patent family members in twenty-three countries.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

Generic name: safinamide mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2026
Generic Entry Controlled by: Canada Patent 2,653,012

XADAGO is a drug marketed by Mdd Us. There are three patents protecting this drug.

This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO

See drug price trends for XADAGO.

The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.

Generic name: ferric pyrophosphate citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2026
Generic Entry Controlled by: Canada Patent 2,550,493
Patent Title: EMBALLAGE DU PYROPHOSPHATE FERRIQUE POUR DIALYSE (PACKAGING OF FERRIC PYROPHOSPHATE FOR DIALYSIS)

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

This drug has thirteen patent family members in eleven countries.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.

Generic name: bupropion hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: Canada Patent 2,578,626
Patent Title: FORMULATIONS A LIBERATION MODIFIEE D'UN SEL DE BUPROPION (MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT)

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering APLENZIN

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

Generic name: bosutinib monohydrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,613,053
Patent Title: FORMES CRISTALLINES DE 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE,ET LEURS PROCEDES DE PREPARATION (CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARBONITRILE ANDMETHODS OF PREPARING THE SAME)

BOSULIF is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF

See drug price trends for BOSULIF.

The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318

BYDUREON is a drug marketed by Astrazeneca Ab. There are eleven patents protecting this drug.

This drug has three hundred and forty-six patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,985,797

BYDUREON is a drug marketed by Astrazeneca Ab. There are eleven patents protecting this drug.

This drug has three hundred and forty-six patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318

FARXIGA is a drug marketed by Astrazeneca Ab. There are nineteen patents protecting this drug and one Paragraph IV challenge. Sixteen tentatively approved generics are ready to enter the market.

This drug has four hundred and fifty patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,985,797

FARXIGA is a drug marketed by Astrazeneca Ab. There are nineteen patents protecting this drug and one Paragraph IV challenge. Sixteen tentatively approved generics are ready to enter the market.

This drug has four hundred and fifty patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318

QTERN is a drug marketed by Astrazeneca Ab. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and thirteen patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,985,797

QTERN is a drug marketed by Astrazeneca Ab. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and thirteen patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: simeprevir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 28, 2026
Generic Entry Controlled by: Canada Patent 2,616,580
Patent Title: INHIBITEURS MACROCYCLIQUES DU VIRUS DE L'HEPATITE C (MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS)

OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.

This drug has one hundred and forty patent family members in forty-three countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

Generic name: benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 02, 2026
Generic Entry Controlled by: Canada Patent 2,617,681
Patent Title: REVETEMENT PAR UN OXYDE METALLIQUE D'INGREDIENTS HYDROINSOLUBLES (METAL OXIDE COATING OF WATER INSOLUBLE INGREDIENTS)

EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has fifty-one patent family members in fifteen countries. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the benzoyl peroxide profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2026
Generic Entry Controlled by: Canada Patent 2,619,475
Patent Title: COMPOSITIONS PHARMACEUTIQUES A LIBERATION CONTROLEE DESTINEES A DES MEDICAMENTS ACIDO-LABILES (CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGS)

CREON is a drug marketed by

This drug has fifty-one patent family members in fifteen countries.

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2026
Generic Entry Controlled by: Canada Patent 2,619,477
Patent Title: NOYAUX CONSTITUES DE MICROGRANULES DE PANCREATINE ADAPTES A UN ENROBAGE ENTERIQUE (PANCREATIN MICROPELLET CORES SUITABLE FOR ENTERIC COATING)

CREON is a drug marketed by

This drug has fifty-one patent family members in fifteen countries.

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 16, 2026
Generic Entry Controlled by: Canada Patent 2,635,680
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 16, 2026
Generic Entry Controlled by: Canada Patent 2,635,680
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)

KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 18, 2026
Generic Entry Controlled by: Canada Patent 2,619,591
Patent Title: COMPOSES ORGANIQUES FERRIQUES DE QUALITE PHARMACEUTIQUE AINSI QU'UTILISATION DE CEUX-CI ET PROCEDES DE FABRICATION DE CEUX-CI (PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME)

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 18, 2026
Generic Entry Controlled by: Canada Patent 3,050,453
Patent Title: COMPOSES ORGANIQUES FERRIQUES DE QUALITE PHARMACEUTIQUE AINSI QU'UTILISATION DE CEUX-CI ET PROCEDES DE FABRICATION DE CEUX-CI (PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME)

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: hydrocodone bitartrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 15, 2026
Generic Entry Controlled by: Canada Patent 2,699,142
Patent Title: FORMULATION MEDICAMENTEUSE CONTRE L'ABUS (ABUSE RESISTANT DRUG FORMULATION)

VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER

The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.

Generic name: pirfenidone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: Canada Patent 2,620,380

ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET

See drug price trends for ESBRIET.

The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.

Generic name: benzgalantamine gluconate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: Canada Patent 2,623,114
Patent Title: AMPLIFICATEURS CHOLINERGIQUES DE PERMEABILITE DE LA BARRIERE SANG-CERVEAU AMELIOREE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNEES D'UNE DEFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT)

ZUNVEYL is a drug marketed by Alpha Cognition. There are three patents protecting this drug.

This drug has twenty-six patent family members in seventeen countries. There has been litigation on patents covering ZUNVEYL

The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.

Generic name: lenalidomide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,570,755
Patent Title: METHODES DE TRAITEMENT DE CERTAINES FORMES DE LEUCEMIE AU MOYEN DE 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDIN-2,6-DIONE (METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE FOR TREATMENT OF CERTAIN LEUKEMIAS)

REVLIMID is a drug marketed by Bristol Myers Squibb. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has three hundred and thirty-one patent family members in forty-one countries. There has been litigation on patents covering REVLIMID

See drug price trends for REVLIMID.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.

Generic name: lenalidomide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,972,299
Patent Title: METHODES DE TRAITEMENT DE CERTAINES FORMES DE LEUCEMIE AU MOYEN DE 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDIN-2,6-DIONE (METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE FOR TREATMENT OF CERTAIN LEUKEMIAS)

REVLIMID is a drug marketed by Bristol Myers Squibb. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has three hundred and thirty-one patent family members in forty-one countries. There has been litigation on patents covering REVLIMID

See drug price trends for REVLIMID.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.

Generic name: olaparib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 17, 2026
Generic Entry Controlled by: Canada Patent 2,664,275

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: Canada Patent 2,626,956
Patent Title: DERIVE DE CARBAMOYLPYRIDONE POLYCYCLIQUE AYANT UNE ACTIVITE D'INHIBITION SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE)

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-six patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: sacubitril; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Canada Patent 2,590,511
Patent Title: COMBINAISON PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTEUR D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)

ENTRESTO SPRINKLE is a drug marketed by Novartis. There are four patents protecting this drug.

This drug has one hundred and forty-five patent family members in forty-three countries. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Canada Patent 2,898,514
Patent Title: AMIDES PEPTIDIQUES SYNTHETIQUES ET DIMERES DE CES AMIDES (SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF)

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

Generic name: crizotinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 23, 2026
Generic Entry Controlled by: Canada Patent 2,632,283

XALKORI is a drug marketed by Pf Prism Cv. There are five patents protecting this drug.

This drug has one hundred and fifty-two patent family members in forty-eight countries.

See drug price trends for XALKORI.

The generic ingredient in XALKORI is crizotinib. One supplier is listed for this generic product. Additional details are available on the crizotinib profile page.

Generic name: fluciclovine f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Canada Patent 2,629,227
Patent Title: COMPOSE PRECURSEUR DE COMPOSE ORGANIQUE MARQUE A L'HALOGENE RADIOACTIF (PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN LABELED ORGANIC COMPOUND)

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.

This drug has thirty patent family members in sixteen countries. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.

Generic name: ganaxolone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Canada Patent 2,631,233

ZTALMY is a drug marketed by Marinus. There are eleven patents protecting this drug.

This drug has forty-eight patent family members in sixteen countries. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.

Generic name: bedaquiline fumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Canada Patent 2,668,512

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

This drug has ninety-seven patent family members in thirty-nine countries.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.

Generic name: ingenol mebutate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Canada Patent 2,634,073
Patent Title: COMPOSITIONS THERAPEUTIQUES (THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE)

PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.